BR112022020628A2 - Métodos para tratamento de anemia usando uma armadilha de ligante de actriib e fedratinibe - Google Patents

Métodos para tratamento de anemia usando uma armadilha de ligante de actriib e fedratinibe

Info

Publication number
BR112022020628A2
BR112022020628A2 BR112022020628A BR112022020628A BR112022020628A2 BR 112022020628 A2 BR112022020628 A2 BR 112022020628A2 BR 112022020628 A BR112022020628 A BR 112022020628A BR 112022020628 A BR112022020628 A BR 112022020628A BR 112022020628 A2 BR112022020628 A2 BR 112022020628A2
Authority
BR
Brazil
Prior art keywords
actriib
methods
anemia
treatment
subject
Prior art date
Application number
BR112022020628A
Other languages
English (en)
Portuguese (pt)
Inventor
Laadem Abderrahmane
Ritland Steve
T Backstrom Jay
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of BR112022020628A2 publication Critical patent/BR112022020628A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
BR112022020628A 2020-04-13 2021-04-12 Métodos para tratamento de anemia usando uma armadilha de ligante de actriib e fedratinibe BR112022020628A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063009400P 2020-04-13 2020-04-13
PCT/US2021/026816 WO2021211418A1 (en) 2020-04-13 2021-04-12 Methods for treating anemia using an actriib ligand trap and fedratinib

Publications (1)

Publication Number Publication Date
BR112022020628A2 true BR112022020628A2 (pt) 2022-11-29

Family

ID=78085002

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022020628A BR112022020628A2 (pt) 2020-04-13 2021-04-12 Métodos para tratamento de anemia usando uma armadilha de ligante de actriib e fedratinibe

Country Status (10)

Country Link
US (1) US20230181690A1 (cg-RX-API-DMAC7.html)
EP (1) EP4135736A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023523568A (cg-RX-API-DMAC7.html)
KR (1) KR20230003502A (cg-RX-API-DMAC7.html)
CN (1) CN115427056A (cg-RX-API-DMAC7.html)
AU (1) AU2021256419A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022020628A2 (cg-RX-API-DMAC7.html)
IL (1) IL297258A (cg-RX-API-DMAC7.html)
MX (1) MX2022012610A (cg-RX-API-DMAC7.html)
WO (1) WO2021211418A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41119A (fr) * 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
EP3227675B1 (en) * 2014-12-03 2023-03-15 Celgene Corporation Activin-actrii antagonists and uses for treating myelodysplastic syndrome
CA2983440C (en) * 2015-04-22 2024-03-12 Alivegen Usa Inc. Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases
TWI814187B (zh) * 2015-05-13 2023-09-01 美商西建公司 使用ACTRII配位體捕捉以治療β-地中海型貧血
LT3490582T (lt) * 2016-07-27 2024-07-25 Acceleron Pharma Inc. Kompozicijos, skirtos naudoti gydant mielofibrozę
US11202818B2 (en) * 2016-09-14 2021-12-21 President And Fellows Of Harvard College Methods and compositions for modulating erythropoiesis
JOP20190085A1 (ar) * 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
WO2018231905A1 (en) * 2017-06-14 2018-12-20 Celgene Corporation Methods for treating myeloproliferative neoplasm-associated myelofibrosis and anemia
MX2021001985A (es) * 2018-08-21 2021-04-28 Sierra Oncology Inc Metodos agnosticos de conteo de plaquetas para tratar la mielofibrosis.
MA53745A (fr) * 2018-09-25 2021-08-04 Impact Biomedicines Inc Procédés de traitement de troubles myéloprolifératifs

Also Published As

Publication number Publication date
AU2021256419A1 (en) 2022-10-20
IL297258A (en) 2022-12-01
EP4135736A1 (en) 2023-02-22
WO2021211418A1 (en) 2021-10-21
US20230181690A1 (en) 2023-06-15
MX2022012610A (es) 2022-11-07
KR20230003502A (ko) 2023-01-06
CN115427056A (zh) 2022-12-02
JP2023523568A (ja) 2023-06-06
EP4135736A4 (en) 2024-06-26

Similar Documents

Publication Publication Date Title
Cavaletti Chemotherapy‐induced peripheral neurotoxicity (CIPN): what we need and what we know
Shin et al. Efficacy of perioperative intravenous iron therapy for transfusion in orthopedic surgery: a systematic review and meta-analysis
Zagari et al. Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study
Macdougall et al. Conference Participants. Iron management in chronic kidney disease: conclusions from a" kidney disease: improving global outcomes"(KDIGO) controversies conference
BR112021024310A2 (pt) Peptidomiméticos para o tratamento de infecções por coronavírus e picornavírus
BR112017023904A2 (pt) derivados indol mono- ou dissubstituídos como inibidores da replicação viral da dengue
BR112019003989A2 (pt) métodos de utilização de um anticorpo biespecífico que reconhece o fator de coagulação ix e/ou o fator de coagulação ix ativado e o fator de coagulação x e/ou o fator de coagulação x ativado
MX383866B (es) Inhibidores de ezh2 para tratar linfomas.
BR112023001956A2 (pt) Composto de fórmula (ia), (ib), (ic) ou (ii), composição farmacêutica, composto para uso ou composição farmacêutica para uso em um método de tratamento de câncer
EA201890009A1 (ru) Ингибиторы ezh2 для лечения лимфомы
BR112017028132A2 (pt) métodos de tratamento de malignidade hematológica usando terapia combinada de inibidor de mtor em nanopartícula
BR112016009669A8 (pt) produtos farmacêuticos, método para tratar câncer e uso de um composto
BR112017015123A2 (pt) derivados de indol como inibidores da replicação viral do dengue
BR112015000660A8 (pt) uso de uma terapia de primeira linha e uma terapia de segunda linha para tratamento de um paciente possuindo uma doença, desordem ou condição associada com uma expressão elevada de um antígeno de tumor, e de uma composição para reduzir ou evitar um efeito adverso associado com a administração de uma célula geneticamente modificada para expressar um car.
BR112018011803A2 (pt) método e mecanismo para a administração de gases incluindo óxido nítrico
JOP20200031A1 (ar) طرق لعلاج الالتهاب العظمي المفصلي باستخدام هلام من كانابيديول عبر الأدمة
BR112017007708A2 (pt) composto macrocíclicos, uso de um composto macrocíclicos, método para tratamento, unidade de dose, composição farmacêutica e método para tratar câncer em um paciente
BR112017006708A2 (pt) indóis mono- ou dissubstituídos como inibidores da replicação viral de dengue
BR112018068676A2 (pt) derivados de indol substituídos como inibidores da replicação viral do dengue
BR112022004519A2 (pt) Composições que compreendem citisina no tratamento e/ou prevenção de vício em sujeitos em necessidade do mesmo
BR112022023928A2 (pt) Uso de canabidiol para o tratamento do transtorno do espectro autista
BR112015022846A2 (pt) uso de um composto para tratar ou prevenir um angioedema mediado pelo receptor b2 da bradicinina e formulação compreendendo o mesmo
BR112018076639A2 (pt) quimioterapias de combinação
BR112020010856A8 (pt) Uso de conjugado de anticorpo anti-her2-fármaco no tratamento de carcinoma urotelial
EP2451299A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF THYROUGH-INFLAMMATORY DISEASES WITH REDUCED FOLDS